ABT-702

ABT-702 (Adenosine Kinase Inhibitor) is a potent, orally active, and selective adenosine kinase (AK) inhibitor with an IC₅₀ of 1.7 nM. ABT-702 shows >1300-fold selectivity for AK over other biological targets, including cyclooxygenases-1 and -2. ABT-702 attenuates inflammation in diabetic retinopathy by increasing free adenosine levels. ABT-702 shows analgesic and anti-inflammatory effects in vivo. ABT-702 can be used for diabetic retinopathy research^[1][2][3]. IC50 & Target:IC50: 1.7 nM (Adenosine kinase, AK)^[1] In Vitro:ABT-702 (5-50 μM, 30 min) inhibits amadori-glycated-albumin (AGA)-induced TNF-α release in a dose-dependent manner in AGA-treated microglial cells via the adenosine A₂AA receptor (A2AAR)^[2]. In Vivo:ABT-702 (0.6-100 µmol/kg, i.p. or p.o., single dose) shows dose-dependent analgesic and anti-inflammatory effects in rats^[1].
ABT-702 (1.5 mg/kg, i.p., twice a week for 8 weeks) meliorates diabetic retinopathy in mice by attenuating retinal inflammation, oxidative stress, and cell death^[2].
ABT-702 (3 mg/kg, i.p., 10 minutes pre-FDG) induces significant regional hypometabolism in the cerebellum, mesencephalic region, and medulla in rats^[3].